Duck and cover

Biopharmaceutical industry CEOs and lobbyists tell BioCentury they have settled on a duck and cover strategy for coping with President-elect Donald Trump’s frontal attacks on the industry’s pricing policies and global supply chains.

The idea is to avoid antagonizing Trump by directly responding to him or launching an aggressive public defense, while quietly shoring up alliances with lawmakers whose votes would be needed to implement the most drastic drug price-control proposals. ...